A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Yvonne McGrath Biography and Net Worth

VP of iTeos Therapeutics

Yvonne joined iTeos in 2020 as Vice-President of Research & Development. With more than 20 years of international experience in oncology drug discovery and development, she has taken lead candidates from early stage research into clinical trials. Immediately prior to iTeos, she served as CSO and board member in Complix, a company developing novel biologics. She has also lead R&D activities in UK based biotech companies including Immunocore and Biovex.

Yvonne holds a PhD from the University of Wales, College of Medicine.

What is Yvonne McGrath's net worth?: The estimated net worth of Yvonne McGrath is at least $83,709.12 as of June 8th, 2021. Ms. McGrath owns 7,927 shares of iTeos Therapeutics stock worth more than $83,709 as of April 19th. This net worth evaluation does not reflect any other assets that Ms. McGrath may own. Learn More about Yvonne McGrath's net worth.
How old is Yvonne McGrath?: Ms. McGrath is currently 50 years old. There are 4 older executives and no younger executives at iTeos Therapeutics. The oldest executive at iTeos Therapeutics is Dr. Michel Detheux Ph.D., President, CEO & Director, who is 57 years old. Learn More on Yvonne McGrath's age.
How do I contact Yvonne McGrath?: The corporate mailing address for Ms. McGrath and other iTeos Therapeutics executives is , , . iTeos Therapeutics can also be reached via phone at 339-217-0161 and via email at [email protected]. Learn More on Yvonne McGrath's contact information.
Has Yvonne McGrath been buying or selling shares of iTeos Therapeutics?: Yvonne McGrath has not been actively trading shares of iTeos Therapeutics in the last ninety days. Most recently, Yvonne Mcgrath sold 10,000 shares of the business's stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $36.76, for a transaction totalling $367,600.00. Learn More on Yvonne McGrath's trading history.
Who are iTeos Therapeutics' active insiders?: iTeos Therapeutics' insider roster includes Detlev Biniszkiewicz (Director), Michel Detheux (CEO), Ansbert Gadicke (Major Shareholder), Matthew Gall (CFO), David Hallal (Director), Les Korsh (VP), Joanne Lager (Insider), and Yvonne McGrath (VP). Learn More on iTeos Therapeutics' active insiders.
Are insiders buying or selling shares of iTeos Therapeutics?: During the last year, iTeos Therapeutics insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $41,850.00. During the last year, insiders at the sold shares 1 times. They sold a total of 350,000 shares worth more than $5,691,000.00. The most recent insider tranaction occured on October, 12th when CFO Matthew Gall bought 5,000 shares worth more than $41,850.00. Insiders at iTeos Therapeutics own 10.2% of the company. Learn More about insider trades at iTeos Therapeutics.
Information on this page was last updated on 10/12/2023.

Yvonne McGrath Insider Trading History at iTeos Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2022	Sell	10,000	$36.76	$367,600.00
6/8/2021	Sell	7,927	$20.00	$158,540.00	7,927
5/24/2021	Sell	7,927	$21.92	$173,759.84	7,927

Yvonne McGrath Buying and Selling Activity at iTeos Therapeutics

iTeos Therapeutics Company Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $10.56

$10.01

$10.61

50 Day Range

MA: $11.39

$9.89

$13.64

2 Week Range

Now: $10.56

$8.20

$18.24

Volume

943,393 shs

Average Volume

277,556 shs

Market Capitalization

$378.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad